For Pharma / Biotech.
EasyM has been demonstrated to be an effective MRD assay for patients undergoing treatment for Multiple Myeloma in the clinic. The achievement of MRD negativity is strongly correlated with Progression Free Survival (PFS) and meets the criteria for PFS surrogacy.
EasyM has been demonstrated to be an effective MRD assay for patients undergoing treatment for Multiple Myeloma in the clinic. The achievement of MRD negativity is strongly correlated with Progression Free Survival (PFS) and meets the criteria for PFS surrogacy.
For Clinical Trials.
If you are running a clinical trial for Multiple Myeloma therapy, please consider including EasyM for better disease monitoring. It can provide:
- At least 10 months earlier detection of relapse
- An ideal complement to other MRD assays for a more accurate MRD status
- Ease of recruitment into the trial – since it does not require bone-marrow aspiration and is more accessible outside of major cities (only requires a blood draw)
- More frequent testing
Please contact us to discuss pricing and logistics for your clinical trial. Pricing is likely to be on the same order of magnitude as NGS-based tests but follows a different structure.
Research Use.
Note that EasyM is seeking certification as a Laboratory Developed Test (LDT) by CLIA and by Health Canada. At present it can be used for research purposes and in a clinical trial for a novel therapeutic (or therapeutic application), but its results are not yet certified to be shared with patients or to direct clinical decisions.
Contact us to discuss how to use EasyM in your clinical trials.